Diagnostic significance of carcinoembryonic antigen and anti-MDA5 antibodies in polymyositis/dermatomyositis-associated rapidly progressive interstitial lung disease
Medicina Clínica · 2025
DOI: 10.1016/j.medcli.2025.107048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medicina Clínica, 2025. Verfasst von Pengfang Tang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China. Electronic address: 1…. Hauptthemen laut MEDLINE: Lung Diseases, Interstitial, Carcinoembryonic Antigen, Dermatomyositis, Interferon-Induced Helicase, IFIH1. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To explore relationship between lung cancer-related biomarkers and polymyositis/dermatomyositis (PM/DM) complicated with interstitial pneumonia, so as to identify serological markers for PM/DM rapidly progressing interstitial pneumonia (RP-ILD). METHODS: This study was a control study in which clinical and laboratory data were collected from the Fujian Medical University Affiliated Second Hospital between August 2019 and January 2024. The tumor markers assessed included carcinoembryonic antigen (CEA), cytokeratin-19 fragment (CYFRA21-1), and neuron-specific enolase (NSE). The study aimed to compare clinical indicators and lung cancer biomarker differences among patients with PM/DM exhibiting varying characteristics. Data analysis was conducted using Spearman's rank correlation, logistic regression analysis, and receiver operating characteristic (ROC) curve analysis. RESULTS: The study included a total of 130 patients, of whom 99 (76.15%) were diagnosed with interstitial lung disease (ILD). Among these, 73 patients had chronic ILD, while 26 exhibited RP-ILD. The remaining 31 individuals (23.85%) did not have ILD. In terms of clinical symptoms, the incidence of Gottron's sign and shortness of breath was significantly higher in the RP-ILD group compared to the chronic ILD and non-ILD groups. In terms of clinical markers, RP-ILD patients had much higher levels of serum ferritin, CEA, and CYFRA21-1 than those with chronic ILD (C-ILD) and non-ILD (N-ILD). Conversely, the RP-ILD group showed significantly reduced values for the oxygenation index, forced vital capacity, carbon monoxide diffusion capacity, and CD3+CD4+ T cell counts compared to the other groups. A significant correlation was observed between the presence of anti-melanoma differentiation-associated gene 5 (MDA5) antibodies, serum CEA levels, CD3+CD4+ T cell ratio, and oxygenation index with PM/DM complicated by RP-ILD. The combination of serum CEA levels and anti-MDA5 antibodies demonstrated the highest diagnostic value for PM/DM-RPILD, demonstrating a sensitivity of 88.9% and a specificity of 81.6%, with an area under the curve of 0.923 (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China. Electronic address: 13600772660@163.com.
- Division of Rheumatology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
Zitieren
APA
Tang, P., Hong, W., Chen, B., & Shi, H. (2025). Diagnostic significance of carcinoembryonic antigen and anti-MDA5 antibodies in polymyositis/dermatomyositis-associated rapidly progressive interstitial lung disease. Medicina Clínica. https://doi.org/10.1016/j.medcli.2025.107048
Vancouver
Tang P, Hong W, Chen B, Shi H. Diagnostic significance of carcinoembryonic antigen and anti-MDA5 antibodies in polymyositis/dermatomyositis-associated rapidly progressive interstitial lung disease. Medicina Clínica. 2025. doi:10.1016/j.medcli.2025.107048
BibTeX
@article{Tang2025,
author = {Tang, Pengfang and Hong, Wengting and Chen, Binbin and Shi, Hongying},
title = {Diagnostic significance of carcinoembryonic antigen and anti-MDA5 antibodies in polymyositis/dermatomyositis-associated rapidly progressive interstitial lung disease},
journal = {Medicina Clínica},
year = {2025},
doi = {10.1016/j.medcli.2025.107048}
}
EUVIMED